[HTML][HTML] Semaglutide and cardiovascular outcomes in obesity without diabetes
AM Lincoff, K Brown-Frandsen… - … England Journal of …, 2023 - Mass Medical Soc
Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
JD Hove… - The New England journal …, 2023 - research.regionh.dk
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown
to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
[PDF][PDF] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
AM Lincoff, K Brown‑Frandsen, HM Colhoun… - 2023 - simdo.it
BACKGROUND Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown
to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
[PDF][PDF] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
AM Lincoff, K Brown‑Frandsen, HM Colhoun… - 2023 - emergencymed.org.il
BACKGROUND Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown
to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
AM Lincoff, K Brown-Frandsen… - … England Journal of …, 2023 - discovery.ucl.ac.uk
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown
to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
AM Lincoff, K Brown-Frandsen… - The New England …, 2023 - europepmc.org
Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
AM Lincoff, K Brown‑Frandsen… - New England …, 2023 - researchinformation.amsterdamumc …
BACKGROUND Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown
to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
A Lincoff, K Brown-Frandsen, H Colhoun… - THE NEW ENGLAND …, 2023 - iris.unipa.it
BackgroundSemaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
[PDF][PDF] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
AM Lincoff, K Brown‑Frandsen, HM Colhoun… - N Engl J …, 2023 - medicab.hc.edu.uy
BACKGROUND Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown
to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
AM Lincoff, K Brown‑Frandsen… - New England Journal …, 2023 - research.rug.nl
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown
to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …
to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …